Synergy Innovation Extends DSK Sale Balance Payment Deadline to July 28 Without Altering Core Terms
Synergy Innovation announced a correction disclosure on June 29, 2026, extending the balance payment date for the sale of its subsidiary DSK shares from June 29 to July 28, 2026.
The extension follows the buyer's request, with the long stop date moved to July 30, and an additional deposit of 1.5 billion won introduced under a supplementary agreement.
The total sale amount of 45 billion won and other key contract terms remain unchanged; the fulfillment of preconditions including MFDS approval for botulinum toxin remains critical for closing.
The counterparty YunJin Partners is a small consulting firm with capital of only 100 million won, continuing to cast uncertainty on the timely payment of the balance.
[AI Summary]This correction is an administrative update extending the payment deadline with no change to the sale amount or core terms, limiting immediate stock price impact. However, the buyer's weak capital base and conditional contract structure remain risk factors requiring investor vigilance.
KOSDAQ Filing Information
[Correction of Description] Report on Major Matters (Decision on Transfer of Stocks and Investment Securities of Other Corporations)